Literature DB >> 27793755

Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

Sai Prachetan Balguri1, Goutham R Adelli1, Soumyajit Majumdar2.   

Abstract

PURPOSE: The objective of the present study was to formulate indomethacin (IN)-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) and to investigate their potential use in topical ocular delivery.
METHODS: IN SLNs (0.1% w/v) and NLCs (0.8% w/v) were prepared, characterized and evaluated. Their in vitro release and flux profiles across the cornea and sclera-choroid-RPE (trans-SCR) tissues and in vivo ocular tissue distribution were assessed. Furthermore, chitosan chloride (CS) (mol. wt.<200kDa), a cationic and water-soluble penetration enhancer, was used to modify the surface of the SLNs, and its effect was investigated through in vitro transmembrane penetration and in vivo distribution tissue studies.
RESULTS: For the IN-SLNs, IN-CS-SLNs and IN-NLCs, the particle size was 226±5, 265±8, and 227±11nm, respectively; the zeta potential was -22±0.8, 27±1.2, and -12.2±2.3mV, respectively; the polydispersity index (PDI) was 0.17, 0.30, and 0.23, respectively; and the entrapment efficiency (EE) was 81±0.9, 91.5±3.2 and 99.8±0.2%, respectively. The surface modification of the SLNs with CS increased the ocular penetration of IN. The NLCs maintained significantly higher IN concentrations in all ocular tissues tested compared to the other formulations evaluated in vivo.
CONCLUSION: The results suggest that lipid-based particulate systems can serve as viable vehicles for ocular delivery. The NLC formulations demonstrated increased drug loading capability, entrapment and delivery to anterior and posterior segment ocular tissues. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27793755      PMCID: PMC5345266          DOI: 10.1016/j.ejpb.2016.10.015

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  50 in total

Review 1.  Colloidal carriers for ophthalmic drug delivery.

Authors:  Rubiana Mara Mainardes; Maria Cristina Cocenza Urban; Priscila Oliveira Cinto; Najeh Maissar Khalil; Marco Vinícius Chaud; Raul Cesar Evangelista; Maria Palmira Daflon Gremiao
Journal:  Curr Drug Targets       Date:  2005-05       Impact factor: 3.465

Review 2.  Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.

Authors:  M Uner
Journal:  Pharmazie       Date:  2006-05       Impact factor: 1.267

3.  Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.

Authors:  Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

Review 4.  Topical Nonsteroidal Anti-inflammatory Drugs and Cataract Surgery: A Report by the American Academy of Ophthalmology.

Authors:  Stephen J Kim; Scott D Schoenberger; Jennifer E Thorne; Justis P Ehlers; Steven Yeh; Sophie J Bakri
Journal:  Ophthalmology       Date:  2015-06-26       Impact factor: 12.079

5.  Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution.

Authors:  P Chetoni; L Panichi; S Burgalassi; U Benelli; M F Saettone
Journal:  J Ocul Pharmacol Ther       Date:  2000-08       Impact factor: 2.671

6.  The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1).

Authors:  Giulia Ranaldi; Iolanda Marigliano; Isabella Vespignani; Giuditta Perozzi; Yula Sambuy
Journal:  J Nutr Biochem       Date:  2002-03       Impact factor: 6.048

Review 7.  Review of ocular drug delivery.

Authors:  Yasmin Sultana; R Jain; M Aqil; Asgar Ali
Journal:  Curr Drug Deliv       Date:  2006-04       Impact factor: 2.565

Review 8.  Application of lipid nanoparticles to ocular drug delivery.

Authors:  Luigi Battaglia; Loredana Serpe; Federica Foglietta; Elisabetta Muntoni; Marina Gallarate; Ana Del Pozo Rodriguez; Maria Angeles Solinis
Journal:  Expert Opin Drug Deliv       Date:  2016-06-24       Impact factor: 6.648

9.  The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial.

Authors:  Mustafa Ilker Toker; Hakan Erdem; Haydar Erdogan; Mustafa Kemal Arici; Aysen Topalkara; Osman Sevki Arslan; Alaaddin Pahsa
Journal:  Am J Ophthalmol       Date:  2006-03-09       Impact factor: 5.258

Review 10.  Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures.

Authors:  Karmani Murugan; Yahya E Choonara; Pradeep Kumar; Divya Bijukumar; Lisa C du Toit; Viness Pillay
Journal:  Int J Nanomedicine       Date:  2015-03-18
View more
  27 in total

1.  Melt-Cast Noninvasive Ocular Inserts for Posterior Segment Drug Delivery.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Akshaya Tatke; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2017-08-01       Impact factor: 3.534

2.  Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  Int J Pharm       Date:  2017-06-17       Impact factor: 5.875

3.  Curcumin-loaded Nanostructured Lipid Carriers for Ocular Drug Delivery: Design Optimization and Characterization.

Authors:  Prit Lakhani; Akash Patil; Pranjal Taskar; Eman Ashour; Soumyajit Majumdar
Journal:  J Drug Deliv Sci Technol       Date:  2018-07-17       Impact factor: 3.981

4.  HDL nanoparticles have wound healing and anti-inflammatory properties and can topically deliver miRNAs.

Authors:  Junyi Wang; Andrea E Calvert; Nihal Kaplan; Kaylin M McMahon; Wending Yang; Kurt Q Lu; Han Peng; C Shad Thaxton; Robert M Lavker
Journal:  Adv Ther (Weinh)       Date:  2020-09-30

Review 5.  [Nanoparticles as drug delivery systems in ophthalmology].

Authors:  M Löscher; J Hurst; L Strudel; M S Spitzer; S Schnichels
Journal:  Ophthalmologe       Date:  2018-03       Impact factor: 1.059

6.  Gellan Gum Based Sol-to-Gel Transforming System of Natamycin Transfersomes Improves Topical Ocular Delivery.

Authors:  Karthik Yadav Janga; Akshaya Tatke; Narendar Dudhipala; Sai Prachetan Balguri; Mohamed Moustafa Ibrahim; Doaa Nabih Maria; Monica M Jablonski; Soumyajit Majumdar
Journal:  J Pharmacol Exp Ther       Date:  2019-03-14       Impact factor: 4.030

7.  Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation.

Authors:  Karthik Yadav Janga; Akshaya Tatke; Sai Prachetan Balguri; Surya P Lamichanne; Mohamed Moustafa Ibrahim; Doaa Nabih Maria; Monica M Jablonski; Soumyajit Majumdar
Journal:  Artif Cells Nanomed Biotechnol       Date:  2018-02-23       Impact factor: 5.678

8.  Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis.

Authors:  Kexin Sun; Ke Hu
Journal:  Drug Des Devel Ther       Date:  2021-01-12       Impact factor: 4.162

9.  Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design.

Authors:  Min-Hwan Kim; Ki-Taek Kim; Seo-Yeon Sohn; Jae-Young Lee; Chang Hyung Lee; Hee Yang; Bo Kyung Lee; Ki Won Lee; Dae-Duk Kim
Journal:  Int J Nanomedicine       Date:  2019-10-25

10.  Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits.

Authors:  Pranjal S Taskar; Akash Patil; Prit Lakhani; Eman Ashour; Waseem Gul; Mahmoud A ElSohly; Brian Murphy; Soumyajit Majumdar
Journal:  Transl Vis Sci Technol       Date:  2019-09-19       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.